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Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study
Young-Hoon Jeong, MD, PHD,* Seung-Whan Lee, MD, PHD,‡ Bong-Ryong Choi, MD,*
In-Suk Kim, MD, PHD,† Myung-Ki Seo, MD,* Choong Hwan Kwak, MD, PHD,*
Jin-Yong Hwang, MD, PHD,* Seong-Wook Park, MD, PHD‡
Jinju and Seoul, Korea
Objectives The purpose of this study was to determine the impact of adjunctive cilostazol in patients with high post-
treatment platelet reactivity (HPPR) undergoing coronary stenting.
Background Although addition of cilostazol to dual antiplatelet therapy enhances adenosine diphosphate (ADP)-induced
platelet inhibition, it is unknown whether adjunctive cilostazol can reduce HPPR.
Methods Sixty patients with HPPR after a 300-mg loading dose of clopidogrel were enrolled. HPPR was defined as maxi-
mal platelet aggregation (Aggmax) 50% with 5 mol/l ADP. Patients were randomly assigned to receive either
adjunctive cilostazol (triple group; n  30) or high maintenance dose (MD) clopidogrel (high-MD group; n  30).
Platelet function was assessed at baseline and after 30 days with conventional aggregometry and the VerifyNow
assay.
Results Baseline platelet function measurements were similar in both groups. After 30 days, significantly fewer patients
in the triple versus high-MD group had HPPR (3.3% vs. 26.7%, p  0.012). Percent inhibitions of 5 mol/l ADP-
induced Aggmax and late platelet aggregation (Agglate) were significantly greater in the triple versus high-MD
group (51.1  22.5% vs. 28.0  18.5%, p  0.001, and 70.9  27.3% vs. 45.3  23.4%, p  0.001, respec-
tively). Percent inhibitions of 20 mol/l ADP-induced Aggmax and Agglate were consistently greater in the triple
versus high-MD group. Percent change of P2Y12 reaction units demonstrated a higher antiplatelet effect in the
triple versus high-MD group (39.6  24.1% vs. 23.1  29.9%, p  0.022).
Conclusions Adjunctive cilostazol reduces the rate of HPPR and intensifies platelet inhibition as compared with a high-MD
clopidogrel of 150 mg/day. (J Am Coll Cardiol 2009;53:1101–9) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.025s
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pt has been established that a combination of a thienopyri-
ine and aspirin improves long-term clinical outcomes in
he setting of percutaneous coronary intervention (PCI) and
cute coronary syndrome (ACS) (1–5). Furthermore, recent
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008, accepted December 8, 2008.tudies have suggested the hypothesis that greater adenosine
iphosphate (ADP)-induced platelet inhibition by a more
otent P2Y12 antagonist may result in greater reduction of
linical ischemic events (6,7). However, because some sub-
roups were perceived to be at high risk of major bleeding
rom greater platelet inhibition, it would be critically im-
ortant to achieve the appropriate degree of platelet inhi-
ition with greater efficacy and without increased bleeding
omplications (6,8).
P2Y12 blockade by clopidogrel at approved doses is rela-
ively modest, and clopidogrel variably inhibits ADP-induced
latelet aggregation (9,10). In addition, clopidogrel resistance,
r high post-treatment platelet reactivity (HPPR) by labora-
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Adjunctive Cilostazol in High Post-PCI Reactivity March 31, 2009:1101–9tory testing, has been associated
with untoward clinical events (11–
16). Although there are limited
data to support clinical benefits, a
higher loading dose (LD) and
maintenance dose (MD) of clopi-
dogrel, and potent P2Y12 antago-
nists have been shown to enhance
platelet inhibition and reduce the
rate of HPPR (17–20).
Cilostazol reversibly inhibits
platelet aggregation via its selective
inhibition of phosphodiesterase
type 3 and results in increased
cyclic adenosine monophosphate
(cAMP) in platelet (21). A recent
study showed that addition of
cilostazol to dual antiplatelet ther-
apy (triple antiplatelet therapy) re-
sulted in greater ADP-induced
platelet inhibition compared with
dual antiplatelet therapy (22). This
finding suggests that triple anti-
platelet therapy could be an al-
ternative regimen to achieve an
enhanced platelet inhibition in
patients with HPPR.
The purpose of this study was
o determine the impact of adjunctive cilostazol on platelet
nhibition in patients with HPPR. We performed a pro-
pective, randomized study to compare the degree of platelet
nhibition by adjunctive cilostazol 100 mg twice daily versus
igh-MD clopidogrel 150 mg/day in patients with HPPR
ndergoing coronary stenting.
ethods
atient population. Patients were eligible for enrollment if
hey were 18 years of age, undergoing coronary stent
mplantation, and identified as having HPPR. Major exclu-
ion criteria included acute myocardial infarction, hemody-
amic instability, active bleeding and bleeding diatheses,
ral anticoagulation therapy with warfarin, use of peripro-
edural glycoprotein IIb/IIIa inhibitors, contraindication to
ntiplatelet therapy, left ventricular ejection fraction 30%,
eukocyte count 3,000/mm3, platelet count 100,000/
m3, aspartate aminotransferase or alanine aminotransfer-
se levels 3 times upper normal, serum creatinine level
2.5 mg/dl, stroke within 3 months, noncardiac disease
ith a life expectancy 1 year, or inability to follow the
rotocol. In patients with multiple lesions, the first stented
esion was considered the target lesion. The Institutional
eview Board of Gyeongsang National University Hospital
pproved the study protocol, and the patients provided
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ADP  adenosine
diphosphate
Agglate  late platelet
aggregation at 5 min
Aggmax  maximal platelet
aggregation
cAMP  cyclic adenosine
monophosphate
HPPR  high post-
treatment platelet
reactivity
IPA  inhibition of platelet
aggregation
LD  loading dose
LTA  light transmittance
aggregometry
MD  maintenance dose
PCI  percutaneous
coronary intervention
PPP  platelet-poor plasma
PRP  platelet-rich plasma
PRU  P2Y12 reaction unitritten informed consent for participation. wtudy design. The ACCEL-RESISTANCE (Adjunctive
ilostazol Versus High Maintenance Dose Clopidogrel in
atients With Clopidogrel Resistance) study is a prospec-
ive, randomized, controlled platelet function study of pa-
ients with HPPR. The flow diagram of the study is depicted
n Figure 1. All patients received a 300-mg LD of clopi-
ogrel and aspirin at least 12 h before coronary stenting
12), followed by 200 mg/day of aspirin thereafter through-
ut the study period. Immediately after insertion of the
rterial sheath in the catheterization laboratory, blood
amples for post-treatment platelet reactivity determina-
ions were obtained. Diagnostic and interventional proce-
ures were performed according to standard techniques. If
atients who met the definition of HPPR were identified,
hey were randomly assigned to adjunctive cilostazol (triple
roup) or high-MD clopidogrel (high-MD group) using
ealed envelopes containing a computer-generated random-
zation sequence. Patients in the triple group (n  30)
eceived a 200-mg LD of cilostazol within 6 h after
andomization, followed by cilostazol 100 mg twice daily for
0 days. Patients in the high-MD group (n  30) received
lopidogrel 150 mg/day for 30 days. At the 30-day
ollow-up visit, patient compliance to antiplatelet therapy
as assessed by interview and tablet counting. Blood
amples at 30 days were obtained for platelet-function
esting 2 to 4 h after the last intake of the study
edication. Peripheral venous blood samples were drawn
rom an antecubital vein using a 21-gauge needle.
latelet function measurements. Blood samples were col-
ected using the double-syringe technique, in which the first
to 4 ml of blood is discarded to avoid spontaneous platelet
ctivation. Platelet function was measured with light trans-
ittance aggregometry (LTA) and the VerifyNow P2Y12
ssay (Accumetrics, San Diego, California).
Platelet aggregation was assessed with LTA according to
tandard protocol (20). Briefly, blood samples were drawn
nto Vacutainer tubes containing 0.5 ml of sodium citrate
.2% (Becton-Dickinson, San Jose, California) and pro-
essed within 60 min. Platelet-rich plasma (PRP) was
btained as a supernatant fluid after centrifuging blood at
00 rpm for 10 min. The remaining blood was further
entrifuged at 2,500 rpm for 10 min to prepare platelet-poor
lasma (PPP). PRP was adjusted to platelet counts of
50,000/l by adding PPP as needed. Platelet aggrega-
ion was assessed at 37°C using a PACKS-4 aggregometer
Helena Laboratories Corp., Beaumont, Texas). Light
ransmission was adjusted to 0% with PRP and to 100%
ith PPP for each measurement. Platelet functions were
easured after addition of 5 and 20 mol/l ADP, and
urves were recorded for 6 min. Platelet aggregation was
easured at peak (Aggmax) and at 5 min (Agglate) by
aboratory personnel blinded to group assignment. Aggmax is
onsidered to reflect the activity of both P2Y1 and P2Y12
eceptors, whereas Agglate is more reflective of P2Y12
eceptor activity. Inhibition of platelet aggregation (IPA)
as defined as the percent decrease of aggregation values
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March 31, 2009:1101–9 Adjunctive Cilostazol in High Post-PCI ReactivityAggmax and Agglate) between baseline and 30 days after
andomization and calculated as follows: IPA (%) 
[intensity of aggregation at baseline  intensity of
ggregation 30 days after randomization]/[intensity of
ggregation at baseline])  100 (18). Percentage of
latelet disaggregation between Aggmax and Agglate was
efined as follows: disaggregation (%)  ([Aggmax 
gglate]/[Aggmax])  100 (18).
The VerifyNow P2Y12 assay is a whole-blood, point-of-
are system, which has been developed to assess responsive-
ess to clopidogrel and other P2Y12 antagonists (23,24).
lood was drawn into a Greiner Bio-One 3.2% citrate
acuette tube (Greiner Bio-One, Kremsmünster, Austria).
he assay device consists of 2 whole-blood assay channels.
ne contains fibrinogen-coated polystyrene beads and
0 mol/l ADP as an agonist. This channel also contains
2 nmol/l PGE1 to reduce the nonspecific contribution
f P2Y1 receptors. Another separate channel contains
brinogen-coated polystyrene beads and iso-thrombin re-
eptor activating protein (iso-TRAP) as an agonist. Platelet
ggregation by iso-TRAP can occur independently of
2Y12 receptors and a baseline value (BASE) for platelet
unction is obtained. BASE values represent the pre-
reatment degree of platelet aggregation in patients on
lopidogrel without weaning off clopidogrel. Results are
eported in P2Y12 reaction unit (PRU), BASE, and percent
latelet inhibition. The percent platelet inhibition is calcu-
ated as: ([BASE-PRU]/BASE) 100, which indicates the
ifference between pre- and post-treatment values. Percent
hange of PRU was calculated as the relative difference of
Figure 1 Flow Diagram of the ACCEL-RESISTANCE Study
HPPR  high post-treatment platelet reactivity.RUs at baseline and 30 days after randomization: percent ehange of PRU (%)  ([PRU at baseline  PRU 30 days
fter randomization]/[PRU at baseline])  100 (24). We
ave previously presented the correlations between results
rom LTA and the VerifyNow P2Y12 assay in our labora-
ory (25).
nd points and definition. The end points of this study
ere the rate of HPPR, IPAs of Aggmax and Agglate with
DP stimuli, percentages of platelet disaggregation, and
ercent change of PRU after 30 days of MD therapy. The
utoff point of HPPR was defined according to baseline
ggmax measured by LTA. Based on previous studies,
atients with 5 mol/l ADP-induced Aggmax 50% were
re-specified as having HPPR (13,26).
ample size calculation and statistical analysis. In the
PTIMUS (Optimizing Antiplatelet Therapy in Diabetes
ellitus) study, a 23.6% increase of IPA was seen with
ncrease of daily MD from 75 to 150 mg (5 mol/l
DP-induced Aggmax 51.2  8% to 39.1  12%) (18). Lee
t al. (22) demonstrated a 58.4% difference of IPA between
0 days of dual and triple antiplatelet therapies (5 mol/l
DP-induced Aggmax 32.2  7.4% to 13.4  9.8%).
ssuming that adjunctive cilostazol would increase IPA by
4.8% over high-MD clopidogrel, at least 23 patients per
roup were required to provide a power of 95% to detect a
tatistically significant difference between groups with a
-sided -level of 0.05. Continuous variables are presented
s mean  SD and compared using the Student unpaired t,
ilcoxon signed rank, or Mann-Whitney U tests. Categor-
cal variables are presented as numbers or percentages and
ere compared using chi-square or Fisher exact tests (if anxpected frequency was 5). A value of p  0.05 was
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Adjunctive Cilostazol in High Post-PCI Reactivity March 31, 2009:1101–9onsidered to indicate statistical significance. Statistical
nalyses were performed using SPSS version 13 (SPSS Inc.,
hicago, Illinois).
esults
atient characteristics and follow-up. Baseline platelet
unction measurements were performed in a total of 300
atients. Of these, 65 patients (21.7%) showed HPPR
nd 60 patients could be enrolled (Fig. 1). Baseline
haracteristics were well matched between study groups
Tables 1 and 2). Baseline platelet aggregation values
Aggmax and Agglate) with 5 and 20 mol/l ADP stimuli
ere similar in the triple group compared with the
igh-MD group (Table 3). Furthermore, baseline PRU and
ercent platelet inhibition did not differ significantly be-
ween groups (Table 4).
Because both treatments were well tolerated and no
ubject discontinued the study drugs, platelet function after
0 days of MD therapy could be assessed in all patients. For
ll patients, the number of remaining tablets demonstrated
omplete compliance with the study protocol. Although
here was 1 patient with tolerable headache in the triple
emographics of the Study Population
Table 1 Demographics of the Study Population
Variables, n (%)
High-MD Group
(n  30)
Triple Group
(n  30) p Value
Age, yrs 63 11 63 9 0.908
Male 20 (66.7) 20 (66.7) 1.000
BMI, kg/m2 25.6 2.8 24.3 3.4 0.205
Diabetes mellitus 5 (16.7) 9 (30.0) 0.360
Hypertension 15 (50.0) 16 (53.3) 1.000
Hypercholesterolemia 6 (20.0) 6 (20.0) 1.000
Current smoking 18 (60.0) 11 (36.7) 0.149
Chronic kidney disease 4 (13.3) 3 (10.0) 0.690
Previous myocardial infarction 2 (6.7) 1 (3.3) 0.557
Previous PCI 4 (13.3) 3 (10.0) 0.690
Previous CABG 0 (0) 0 (0) 1.000
Previous stroke 0 (0) 2 (6.7) 0.154
Concomitant medications
Statin 0.771
CYP 3A4 metabolized 23 (76.7) 21 (70.0)
Non–CYP 3A4 metabolized 5 (16.7) 6 (20.0)
Beta-blocker 22 (73.3) 23 (76.7) 1.000
ACEI 6 (20.0) 7 (23.3) 1.000
ARB 21 (70.0) 19 (63.3) 0.785
Nitrate 25 (83.3) 23 (76.7) 0.748
Calcium-channel blocker 8 (26.7) 6 (20.0) 0.761
LV ejection fraction, % 59 8 60 11 0.769
Hb, g/dl 14.1 1.3 13.6 1.8 0.261
Platelet count, 103/mm3 266 53 257 68 0.579
HbA1C, % 5.9 0.6 6.4 1.3 0.109
Creatinine clearance, ml/min 87 27 92 30 0.576
Total cholesterol, mg/dl 187 49 173 36 0.223
CEI angiotensin-converting enzyme inhibitor; ARB angiotensin receptor blocker; BMI body
ass index; CABG  coronary artery bypass grafting; CYP 3A4  cytochrome P450 3A4soenzyme; Hb hemoglobin; LV left ventricular; MDmaintenance dose; PCI percutaneous
oronary intervention. Aroup, there were no cardiovascular events and no major or
inor bleeding in either group.
ate of HPPR. After 30 days of MD therapy, both groups
howed a remarkable reduction in the rates of HPPR
ompared with baseline values (all values; p  0.001).
urthermore, adjunctive cilostazol significantly reduced the
ate of HPPR relative to high-MD clopidogrel (3.3% vs.
6.7%, p  0.012) (Fig. 2). Similar results were seen when
0 mol/l ADP-induced Aggmax 50% (18) was used to
efine HPPR (26.7% vs. 73.3%, p  0.001).
DP-induced platelet aggregation. Patients in the 2
roups experienced a definite reduction in Aggmax after 30
ays of MD therapy compared with corresponding baseline
easurements (all values; p  0.001). Aggmax values after
esion and Proceduralharacteristics of the Study Population
Table 2 Lesion and ProceduralCharacteristics of the Study Population
Variables, n (%)
High-MD Group
(n  30)
Triple Group
(n  30) p Value
arget vessel 0.769
Left anterior descending artery 16 (53.3) 14 (46.7)
Left circumflex artery 5 (16.7) 8 (26.7)
Right coronary artery 9 (30.0) 7 (23.3)
Left main artery 0 (0) 1 (3.3)
HA/ACC lesion type B2/C 23 (76.7) 21 (70.0) 0.771
ultivessel lesion 15 (50.0) 18 (60.0) 0.465
hrombus present 3 (10.0) 1 (3.3) 0.305
re-dilation 29 (96.7) 30 (100.0) 0.317
ultivessel intervention 8 (26.7) 11 (36.7) 0.580
tent diameter, mm 3.1 0.3 3.2 0.4 0.345
tents per patient 2.4 0.6 2.3 1.2 0.889
otal stent length, mm 31.5 20.7 27.5 12.7 0.371
aximal balloon size, mm 3.41 0.37 3.47 0.52 0.619
aximal inflation pressure, atm 14.8 3.5 15.0 4.3 0.896
CC  American College of Cardiology; AHA  American Heart Association; MD  maintenance
ose.
latelet Function Measurementsy Ligh Transmittance Aggr gometry
Table 3 Platelet Function Measurementsby Light Transmittance Aggregometry
Variables, %
High-MD Group
(n  30)
Triple Group
(n  30) p Value
Maximal aggregation with
5 mol/l ADP
Baseline 61.1 7.8 61.3 7.4 0.943
30 days after randomization 43.9 11.9 29.5 12.7 0.001
Late aggregation with
5 mol/l ADP
Baseline 56.2 10.3 55.0 11.3 0.670
30 days after randomization 30.9 14.5 15.3 13.1 0.001
Maximal aggregation with
20 mol/l ADP
Baseline 72.3 6.6 70.3 6.1 0.222
30 days after randomization 57.2 11.7 42.1 15.6 0.001
Late aggregation with
20 mol/l ADP
Baseline 68.4 9.7 65.4 9.5 0.236
30 days after randomization 45.5 16.6 24.5 19.7 0.001DP  adenosine diphosphate; MD  maintenance dose.
3
l
A
t
I
2
h
c
I
A
r
1
2
t
t
0
d
A
w
w
A
4
d
I
A
r
2
4

b
g
g
s
i
g
g
T
P
3
c
(
h
g
d
i
w
p
D
T
k
Pb
M
1105JACC Vol. 53, No. 13, 2009 Jeong et al.
March 31, 2009:1101–9 Adjunctive Cilostazol in High Post-PCI Reactivity0 days of MD therapy in the triple group were significantly
ower than those in the high-MD group (Table 3). IPAs of
ggmax with ADP stimuli were consistently greater in the
riple group as compared with the high-MD group (Fig. 3).
PA of Aggmax with 5 mol/l ADP stimulus was 51.1 
2.5% in the triple group and 28.0  18.5% in the
igh-MD group, with a mean difference of 23.2% (95%
onfidence interval [CI]: 12.5% to 33.8%; p  0.001). If
PA of Aggmax was assessed after stimulus with 20 mol/l
DP, the triple group achieved a significant reduction
elative to the high-MD group (39.6  23.0% vs. 20.7 
5.7%), with a mean difference of 18.9% (95% CI: 8.7% to
9.1%; p  0.001).
Significant reductions in Agglate after 30 days of MD
herapy were also observed in the 2 groups, compared with
heir corresponding baseline measurements (all values; p 
.001). Agglate values after 30 days of MD therapy were
ifferent between groups (Table 3). IPAs of Agglate with
DP stimulus are illustrated in Figure 4. IPAs of Agglate
ere consistently higher in the triple group as compared
ith the high-MD group. IPA of Agglate with 5 mol/l
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Figure 2 Rate of HPPR After 30 Days of Antiplatelet Therapy
High maintenance dose (MD) group received high-MD clopidogrel of 150 mg/day.
Triple group received adjunctive cilostazol, 100 mg twice daily, in addition
to dual antiplatelet therapy. ADP  adenosine diphosphate; Aggmax  maxi-
mal platelet aggregation; HPPR  high post-treatment platelet reactivity.
latelet Function Measurementsy h VerifyNow P2Y12 Assay
Table 4 Platelet Function Measurementsby the VerifyNow P2Y12 Assay
Variables
High-MD Group
(n  30)
Triple Group
(n  30) p Value
P2Y12 reaction unit
Baseline 285.1 65.5 287.7 72.2 0.881
30 days after randomization 210.5 72.5 175.6 79.4 0.080
Percent platelet inhibition
Baseline 11.8 12.4 11.7 16.2 0.979
30 days after randomization 35.7 20.3 48.4 19.2 0.015
D  maintenance dose.tDP stimulus was 70.9  27.3% in the triple group and
5.3  23.4% in the high-MD group, with a mean
ifference of 25.6% (95% CI: 12.4% to 38.7%; p  0.001).
f IPA of Agglate was assessed after stimulus with 20 mol/l
DP, the triple group showed a significant reduction
elative to the high-MD group (62.1  30.7% vs. 33.1 
2.8%), with a mean difference of 29.0% (95% CI: 15.0% to
3.0%; p  0.001).
Percentages of platelet disaggregation with 5 and 20
mol/l ADP stimuli did not differ between both groups at
aseline (Fig. 5). A significant increase of platelet disaggre-
ation after 30 days of MD therapy was identified in the 2
roups, compared with their corresponding baseline mea-
urements (all values; p 0.001). Thirty days after random-
zation, percentages of platelet disaggregation in the triple
roup showed a greater increase than those of the high-MD
roup (Fig. 5).
he VerifyNow P2Y12 assay. A significant reduction of
RU and an increase of percent platelet inhibition after
0 days of MD therapy were identified in the 2 groups,
ompared with their corresponding baseline measurements
all values; p  0.001). A trend toward lower PRU and
igher percent platelet inhibition was apparent in the triple
roup (Table 4). Percent change of PRU in the triple group
emonstrated greater antiplatelet effect than that achieved
n the high-MD group (39.6  24.1% vs. 23.1  29.9%),
ith a mean difference of 16.5% (95% CI: 2.4% to 30.6%;
 0.022) (Fig. 6).
iscussion
his ACCEL-RESISTANCE study is the first to our
nowledge to demonstrate that adjunctive cilostazol reduces
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Figure 3 Inhibition of Maximal Platelet Aggregation
Between Baseline and 30 Days of Antiplatelet Therapy
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Adjunctive Cilostazol in High Post-PCI Reactivity March 31, 2009:1101–9atients with HPPR undergoing coronary stenting. Fur-
hermore, this study showed that adjunctive cilostazol as
ompared with high-MD clopidogrel of 150 mg/day re-
ulted in fewer patients with HPPR and less platelet
ggregation. These results provide a rationale for further
tudies to assess whether adjunctive cilostazol, as compared
ith other intensified regimens, provides long-term clinical
enefits in patients with HPPR.
Platelet inhibition by standard clopidogrel dose reveals
esponse variability when monitored by in vitro platelet func-
ion assays (27). Furthermore, HPPR has been associated with
dverse clinical outcomes, including stent thrombosis after
tenting or in ACS patients (11–16,28). Adequate platelet
nhibition by P2Y12 antagonists may contribute to decreased
ates of ischemic clinical events. Several strategies have been
nder investigation to achieve adequate platelet inhibition by
lockade of the P2Y12 pathway. Although higher MDs of
lopidogrel have achieved significant improvements in
ntensity of inhibition, persistent presence of HPPR was
pparent (18). In the OPTIMUS study, high-MD clopidogrel
f 150 mg/day was associated with enhanced antiplatelet effects
ompared with standard-MD clopidogrel of 75 mg/day in
igh-risk patients with type 2 diabetes mellitus, but suboptimal
lopidogrel response (20 mol/l ADP-induced Aggmax
50%) was still present in 60% of patients on the 150-mg
egimen. Moreover, because no available clinical study has
hown superiority of high- over standard-MD clopidogrel, few
ractitioners have adopted high-MD clopidogrel. Prasugrel is
novel third-generation thienopyridine with more consistent
nd greater platelet inhibition than a high-MD clopidogrel of
50 mg/day (20,29). As expected, the TRITON–TIMI 38
TRial to assess Improvement in Therapeutic Outcomes by
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yocardial Infarction 38) study found that prasugrel reduced
he frequency of ischemic events by 19% in ACS patients (6,7).
owever, subgroups with advanced age, known cerebrovascu-
ar disease, or low body weight had a high risk of major
leeding and no net benefit from prasugrel (6,8). It is imper-
tive to balance efficacy and safety while achieving adequate
latelet inhibition.
Cilostazol is a selective reversible phosphodiesterase type
inhibitor with unique antithrombotic and vasodilatory
roperties based on its novel mechanism of action (21,29).
ilostazol inhibits platelet aggregation induced by ADP,
rachidonic acid, collagen, and epinephrine (21). The com-
ination of cilostazol and aspirin after stenting showed
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March 31, 2009:1101–9 Adjunctive Cilostazol in High Post-PCI Reactivityith that of thienopyridine and aspirin (30,31). Further-
ore, an observational study showed that triple antiplatelet
herapy reduced the rates of death, myocardial infarction,
arget lesion revascularization, or stent thrombosis after
tenting by approximately 50% as compared with dual
ntiplatelet therapy, without increasing the risk of bleeding
n the triple group (32). The potential to achieve platelet
nhibition with minimal risk of bleeding might be explained
y an endothelium-targeted antithrombotic therapy, that is,
eduction of partially activated platelets by improved endo-
helial function (21).
In recent studies, triple antiplatelet therapy has re-
ulted in more potent inhibition of ADP-induced platelet
ggregation than dual antiplatelet therapy (22,33). This
henomenon may be explained by an additive elevation of
ntracellular cAMP through both increase of cAMP
roduction by clopidogrel and inhibition of cAMP deg-
adation by cilostazol (33). Moreover, the present study
rovides the first laboratory evidence that adjunctive
ilostazol, as compared with high-MD clopidogrel of 150
g/day, may significantly reduce the rate of HPPR and
nhance platelet inhibition in high-risk patients. This
nding might underlie the clinical benefits of triple
ntiplatelet therapy in the prevention of thrombotic
vents after stenting (32). In addition, inhibition of
eointimal proliferation by adjunctive cilostazol has re-
ulted in reduced restenosis and target lesion revascular-
zation rates, not only after bare-metal stent deployment
34), but also after drug-eluting stent implantation in
atients with diabetes mellitus or long lesions, compared
Figure 6 Percent Change of P2Y12 Reaction Unit
Between Baseline and 30 Days of Antiplatelet Therapy
Bars indicate standard deviations.
MD  maintenance dose; PRU  P2Y12 reaction unit.ith dual antiplatelet therapy (35,36). aWith the improvements in both devices and pharmacolog-
cal support for PCI, stent implantation has been performed
ith increasing frequency for more complex lesions, and at
east 60% of current use is off-label (37). Application of triple
ntiplatelet therapy for patients with suboptimal clopidogrel
esponse or complex lesions could be an attractive option to
alance efficacy and safety while achieving adequate platelet
nhibition. Long-term clinical trials with a large number of
atients are needed to verify that adjunctive cilostazol could
mprove clinical outcomes in these patients.
There is no widely acceptable threshold of HPPR (38).
re-procedural HPPR measured by LTA with ADP stim-
lation has been associated with a risk of post-discharge
schemic events after PCI (12,14,26,28,39). However, be-
ause studies have differences in ADP concentration (5, 10,
r 20 mol/l ADP) and measured points (Aggmax vs.
gglate), it is difficult to define an optimal cutoff point for
PPR (38). Bliden et al. (26) demonstrated that patients
ndergoing elective PCI with pre-procedural HPPR (5
mol/l ADP-induced Aggmax 50%) were at increased risk
or recurrent ischemic events (odds ratio: 34.6, 95% CI: 8.3
o 144.2, p  0.001). HPPR measured by the VerifyNow
2Y12 assay (PRU 235) was also associated with post-
ischarge events after drug-eluting stent implantation (23).
ased on previously published data from our laboratory, a 5
mol/l ADP-induced Aggmax 50% on LTA was similar
o a PRU value235 (25). A threshold of HPPR defined as
5 mol/l ADP-induced pre-procedural Aggmax 50%,
sed in the present study, might indicate an acceptable level
f suboptimal response.
tudy limitations. First, the duration of the study period was
hort and the number of study subjects was relatively small.
ariations of pharmacokinetic and pharmacodynamic profiles
n the early phase after initiation of antiplatelet therapy might
ave influenced the results. It needs to be assessed whether the
nhanced antiplatelet activity with addition of cilostazol to dual
ntiplatelet therapy will be consistently maintained after long-
erm administration. Second, because we performed baseline
latelet function measurements at least 12 h after clopidogrel
oading, baseline parameters may not be indicative of those
orresponding to standard-MD clopidogrel of 75 mg/day.
elative change after 30 days of MD therapy may not
epresent exact differences of platelet inhibition between
tandard-MD clopidogrel and the studied regimen. Finally,
TA values can change according to sample conditions and
rocessing. Even though an expert performs the platelet
unction tests and validation tests daily, there may be daily bias
n platelet function measurements. This inherent limitation of
TA, however, should have not significantly influenced the
esults. The consistent findings with the VerifyNow P2Y12
oint-of-care assay may corroborate the results with LTA.
onclusions
mong patients with HPPR undergoing coronary stenting,
djunctive cilostazol reduces the rate of HPPR and achieves
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lopidogrel of 150 mg/day. It needs to be evaluated whether
eduction of HPPR with triple antiplatelet therapy could be
ranslated into improved clinical outcomes.
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